Fresh frozen plasma and recombinant factor VIIa use in neonates

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 12, 2009, Pages 901-906

  Puetz, John ^b   Darling, Ginger ^b   McCormick, Kimberly A ^b   Wofford, Jonathan D ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activated partial thromboplastin time; Fresh frozen plasma; Neonate; Prothrombin time; Recombinant factor VIIa

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; BLOOD CLOTTING TEST; CARDIOPULMONARY BYPASS; DRUG DOSE INCREASE; DRUG SAFETY; FETUS HYDROPS; HEMOPHILIA; HUMAN; MAJOR CLINICAL STUDY; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN INTENSIVE CARE; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; BLOOD CLOTTING DISORDER; BLOOD COMPONENT THERAPY; GESTATIONAL AGE; PLASMA;

BLOOD COAGULATION DISORDERS; BLOOD COMPONENT TRANSFUSION; FACTOR VIIA; GESTATIONAL AGE; HEMORRHAGE; HUMANS; INFANT, NEWBORN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PROTHROMBIN TIME; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 73949123783     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181c29c25     Document Type: Article

References (48)

1. Taeusch H, Ballard R, Gleason C, eds. Avery's Diseases of the Newborn. 8th ed. Philadelphia, PA: Saunders; 2005:1157.
2. Martin R, Fanaroff A, Walsh M. Fanaroff and Martin's Neonatal-Perinatal Medicine. Diseases of the Fetus and Infant. 8th ed. Philadelphia PA: Mosby; 2006:1330.
3. Polin R, Fox W, Abman S. Fetal and Neonatal Physiology. 3rd Ed. Philadelphia, PA: Saunders; 2004:1450.
4. Baer V, Lambert D, Schmuts N, et al. Adherence to NICU transfusion guidelines: data from a multihospital healthcare system. J Perinatol. 2008;28:492-497.
5. Beverley D, Pitts-Tucker T, Congdon P, et al. Prevention of intraventricular haemorrhage by fresh frozen plasma. Arch Dis Child. 1985;60:710-713.
6. Elbourne D, for the Northern Neonatal Initiative Trial Group. A randomized trial comparing the effect of prophylactic intravenous fresh frozen plasma, gelatin, or glucose on early mortality and morbidity in preterm babies. Eur J Pediatr. 1996; 155:580-588.
7. Gross S, Filston H, Anderson J. Controlled study of treatment for disseminated intravascular coagulation in the neonate. Pediatrics. 1982;100:445-448.
8. Stanworth S, Brunskill J, Hyde C, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol. 2004;126:139-152.
9. Johnson C, Snyder M, Weaver R. Effects of fresh frozen plasma infusions on coagulation screening tests in neonates. Arch Dis Child. 1982;57:950-952.
10. Kitchens C. To bleed or not to bleed? Is that the question for the PTT? J Thromb Haemost. 2005;3:2607-2611.
11. Mathew P, Young G. Recombinant factor VIIa in paediatric bleeding disorders-a 2006 review. Haemophilia. 2006;12:457-472.
12. Mayer S, Brun N, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
13. Wong W, Huang W, Miller R, et al. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia. 2000;6:50-54.
14. Duncan A, Benson L, Critz A, et al. Neonatal Coagulopathy treatment with rFVIIa. Pediatr Res. 2001;49:290A.
15. Chuansumrit A, Nuntnarumit P, Okascharoen C, et al. The use of recombinant activated factor VII to control bleeding in a preterm infant undergoing exploratory laparotomy. Pediatrics. 2002;110:169-171.
16. Veldman A, Fischer D, Voigt B, et al. Life Threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med. 2002;28:1636-1637.
17. Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinat. 2002;22:672-674.
18. Griesen G, Rinette B. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis. 2003;14:117-120.
19. Girish M, Rauch R, Carbon R, et al. Refractory bleeding following major surgery of a giant sacrococcygeal teratoma in a premature infant: successful use of recombinant factor VIIa. Eur J Pediatr. 2004;163:118-119.
20. Egan J, Lammi A, Schell D, et al. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med. 2004;30:682-685.
21. Fontaine M, Lazarchick J, Taylor S, et al. Use of recombinant factor VIIa in infants with severe coagulopathy. J Perinat. 2004;24:310-311.
22. Tancabelic J, Haun S. Management of coagulopathy with recombinant factor VIIa in a neonate with echovirus type 7. Pediatr Blood Cancer. 2004;43:170-176.
23. Razon Y, Erez E, Bernardo V, et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Pediatr Anesth. 2005;15:235-240.
24. Pychynska-Pokorska M, Moll J, Krajewski W, et al. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med. 2004; 5:246-250.
25. Velik-Salchner C, Sergi C, Fries D, et al. Use of recombinant factor VIIa (NovoSeven) in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporal membrane oxygenation. Anesth Analg. 2005;101:924.
26. Millar C, Stringer M, Sugarman I, et al. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia. 2005;11:171-174.
27. Filan P, Mills J, Clarnette T, et al. Spontaneous liver hemorrhage during laparotomy for necrotizing enterocolitis: a potential role for recombinant factor VIIa. J Pediatr. 2005; 147:857-859.
28. Wittenstein B, Cho N, Ravn H, et al. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med. 2005;6:473-476.
29. Ekert H, Brizard C, Eyers R, et al. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonany bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis. 2006;17:389-395.
30. Grizelj R, Vukovic J, Filipovic-Grcic B, et al. Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage. Blood Coagul Fibrinolysis. 2006;17:413-415.
31. Cetin H, Yalaz M, Akisu M, et al. The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant. Blood Coagul Fibrinolysis. 2006;17:213-216.
32. Abdullah F, Hunter C, Hargrove C, et al. Recombinant factor VIIa for the treatment of massive liver fracture in a premature infant. J Pediatr Surg. 2006;41:1764-1767.
33. Hunsler C, Kribs A, Eifinger F, et al. Recombinant activated factor seven in acute life-threatening bleeding in neonates: report on three cases and review of literature. J Perinatol. 2006;26:706-713.
34. De Santiago J, Martinez-Garcia E, Giron J, et al. Prophylactic recombinant factor VIIa administration to an infant with congenital system juvenile xanthogranuloma. Pediatr Anesth. 2006;16:974-976.
35. Brady K, Easley R, Tobias J. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage. Pediatr Anesth. 2006;16:1042-1046.
36. Veldman A, Josef J, Fischer D, et al. A prospective pilot study of prophylactic treatment of preterm neonates with recombinant activated factor VII during the first 72 hours of life. Pediatr Crit Care Med. 2006;7:34-39.
37. Fischer D, Schloesser R, Buxmann H, et al. Recombinant activated factorr VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation. J Pediatr Hematol Oncol. 2008;30:337-342.
38. Abdel-Wahab O, Healy B, Dzik W. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion. 2006;46:1279-1285.
39. Seguin J, Topper W. Coagulation studies in very lowbirthweight infants. Am J Perinatol. 1994;1:27-29.
40. Nathan D, Oski F. Hematology of Infancy and Childhood. 4th ed. Philadelphia PA: Saunders; 1993:119-128.
41. Gupta J, Starr H, Fincher P, et al. Intraventricular haemorrhage in the newborn. Med J Aust. 1976;2:338-340.
42. Setzer E, Webb I, Wassenaar J, et al. Platelet dysfunction and coagulopathy in intraventricular hemorrhage in the premature infant. J Pediatr. 1982;4:599-605.
43. Beverly D, Chance G, Inwood M, et al. Intraventricular haemorrhage and haemostasis defects. Arch Dis Child. 1984; 59:444-448.
44. McDonald M, Johnson M, Rumack C, et al. Role of coagulopathy in newborn intracranial hemorrhage. Pediatrics. 1984;74:26-31.
45. Van De Bor M, Briet E, Van Bel F, et al. Hemostasis and periventricular-intraventricular hemorrhage of the newborn. Am J Dis Child. 1986;140:1131-1134.
46. Amato M, Fauchere J, Herman U. Coagulation abnormalities in low birth weight infants with peri-intraventricular hemorrhage. Neuropediatrics. 1988;19:154-157.
47. Salonvaara M, Riikonen P, Kekomaki R, et al. Intraventricular haemorrhage in very-low-birthweight preterm infants: association with low prothrombin activity at birth. Acta Paediatr. 2005;94:807-811.
48. Pusateri A, Park M. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Crit Care. 2005;9(suppl 5):S15-S24.